Health · Pharma & Biotech · 2 hrs ago
Pro티na secures patent filings for osteoarthritis drug candidate in eight markets
South Korean drug developer Protina has advanced patent filings for PRT-101 in eight markets, including the United States, Europe, Japan and China.
PRT-101 is an experimental treatment for osteoarthritis, a condition that damages joints.
The candidate aims to boost cartilage production by targeting the SOX9 protein, using a mechanism Protina describes as first in its class.
The company is also pursuing patent applications in Hong Kong and Singapore.
Protina is discussing licensing deals with several Japanese drugmakers, and has signed confidentiality agreements with two of them as they assess development in Japan.
In South Korea, the company aims to apply to begin a phase 1 trial in the third quarter of 2027.
The patent expansion and licensing talks could support future global partnerships, but PRT-101 remains under development and has not yet begun the planned South Korean trial.
Protina has completed national and regional patent-phase entry for its osteoarthritis drug candidate PRT-101 in eight markets.
The filings cover patents for the candidate’s core substance and therapeutic use.
The company is discussing licensing with several Japanese pharmaceutical companies, and has signed confidentiality agreements with two of them.
PRT-101 targets SOX9, a transcription factor involved in cartilage production.
Protina aims to apply to begin a domestic Phase 1 trial in the third quarter of 2027.
- Who
- Protina, a company developing new drugs.
- What
- It completed patent-phase entry for PRT-101 in eight markets, covering the candidate’s core substance and therapeutic use.
- When
- The company said the filings were completed recently; the report was published on October 29, 2026.
- Where
- The United States, Europe, Japan, China, Canada, Australia, Brazil and Mexico.
- Why
- To expand global patent protection and support overseas licensing and commercialization.
This story does not have two clearly opposing sides.
Protina presented preclinical data for PRT-101 at the European Congress of Rheumatology.
Maeil Business reported that Protina had completed patent-phase entry for PRT-101 in eight markets.
Protina aims to submit an application to begin a domestic Phase 1 trial of PRT-101.
- Candidate
- PRT-101
- Patent markets
- United States, Europe, Japan, China, Canada, Australia, Brazil and Mexico
- Licensing discussions
- Several Japanese pharmaceutical companies
- Confidentiality agreements
- Two Japanese companies
- Planned Phase 1 application
- Third quarter of 2027
What people are saying
Global rights protection and licensing discussions are becoming more concrete, based on successive research achievements across our in-house drug pipeline
We will create tangible commercialization results through successful clinical development of our major pipelines and close cooperation with global pharmaceutical companies